Skip to content

Gastric Pull up Versus Free Flap Reconstruction for Laryngo-pharyngeal Defects

Gastric Pull up Versus Free Flaps Reconstruction (Anterolateral Thigh and Radial Forearm Free Flap) for Laryngo-pharyngeal Defects: A Prospective Randomized Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03171558
Acronym
GPU vs ALT
Enrollment
20
Registered
2017-05-31
Start date
2017-03-16
Completion date
2023-03-31
Last updated
2017-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Neoplasms, Pharyngectomy, Reconstructive Surgical Procedures

Brief summary

This study will compare the gastric pull up (GPU) with the free flap \[(specifically, anterolateral thigh (ALT) and radial forearm free flap (RFFF)\] techniques used in the reconstruction of alimentary tracts in patients who require laryngectomy and circumferential pharyngectomy for carcinoma resection. These two interventions will be compared by block randomizing 20 patients based on history of failed chemoradiation to undergo either ALT or RFFF. The primary outcome will be the type and number of postoperative complications. The secondary outcomes will include swallowing function, speech, and quality of life measures along with cancer specific endpoints.

Interventions

PROCEDUREGastric Pull Up

Using gastric tissue to reconstruct the esophagus and pharynx after pharyngo-esophagectomy.

Using radial forearm free flap or anterolateral thigh free flap to reconstruct the cervical esophagus and pharynx after pharyngectomy and cervical esophagectomy.

Sponsors

University of British Columbia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Willing to provide informed consent, attend follow-up visits and complete questionnaires * Have an Eastern Cooperation Oncology Group (ECOG) performance status of 0-2 * Patients with carcinoma of thyroid, larynx, hypopharynx, or cervical esophagus requiring surgery as a primary treatment modality or after chemoradiation treatment failure * Laryngectomy and circumferential pharyngectomy as recommended by the head and neck tumor board

Exclusion criteria

* Serious medical co morbidities or other contraindications to surgery * Metastatic disease * Pregnant or lactating women * Patients whose clinical circumstances are such that one surgical intervention would be recommended over the other: The cancer extends into the the thorax as seen on pre-operative CT scan. In these patients, the GPU reconstruction is preferred. * Patients who have liver cirrhosis or multiple previous surgeries on the stomach would not be candidates for the GPU and thus will be excluded from the study

Design outcomes

Primary

MeasureTime frameDescription
Type and number of postoperative complicationsWithin 90 days of surgery occurring on the same or separate admission.Complications will be divided by: (1) in-hospital mortality (2) reconstruction related complications (anastomotic leak, fistula formation, flap necrosis, flap stenosis or stricture, requirement for surgical revision), and (3) addition in-hospital complications ( bleeding, pulmonary, cardiac, infectious, abdominal, wound concern)

Secondary

MeasureTime frameDescription
Flap Donor Site Morbidity (RFFF) )Measure documented at 1, 3, 6 and 12 months post-surgery, thereafter yearly for 5 years. (8 visits total)Donor site associated quality of life (Toronto Extremity Salvage Score - Upper Extremity)
Flap Donor Site Morbidity (ALT)Measure documented at 1, 3, 6 and 12 months post-surgery, thereafter yearly for 5 years. (8 visits total)Donor site associated quality of life (Toronto Extremity Salvage Score - Lower Extremity)
Time to return to swallowingIf occurs in hospital will be documented by the treating team. Otherwise will be documented based on patient or speech language pathology reporting at 1, 3, 6 and 12 months post-surgery, thereafter yearly for 5 years. (9 visits total)Time from surgery to swallowing liquids.
Operative blood lossInitial surgeryTotal volume of blood lost and accounted for in suction canisters as documented in nursing charts. (this excludes blood not accounted for in the suction containers)
Operative ParametersDuring initial surgery and within the first 72 hours.Requirement for transfusion, measured in units of blood.
Time to return of FULL oral dietMeasure documented at 1, 3, 6 and 12 months post-surgery, thereafter yearly for 5 years. (9 visits total)Time from surgery to return of diet that is sufficient for patient to maintain nutrition without requiring G-tube or NG feeding. Patient or Speech Language Pathology reported.
Requirement for feeding tube at 1 year after surgery.Documented at 1 year follow up visit.Whether patients are still feeding tube dependent for nutrition at 1 year follow up.
Surgical TimeInitial SurgeryTime from first incision to the end of surgical closure as documented on the nursing record.
DysphagiaMeasure documented at time of surgical booking and at 1, 3, 6 and 12 months post-surgery, thereafter yearly for 5 years. (9 visits total)M.D. Anderson Dysphagia Inventory for assessment of dysphagia
Dumping SymptomsMeasure documented at time of surgical booking and at 1, 3, 6 and 12 months post-surgery, thereafter yearly for 5 years. (9 visits total)Assessed with the dumping symptom rating scale
Quality of LifeMeasure documented at 1, 3, 6 and 12 months post-surgery, thereafter yearly for 5 years. (8 visits total)Measure with combined scores of two questionnaires: European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ) - C30 and EORTC QLQ - H&N35
Margin status of the resected specimen as reported by pathologyAt the time of surgeryWill be classified as positive and negative based on what is reported at Vancouver General Hospital Pathology reports generated at the time of surgery. A measure of clearance in millimeters will also be provided.
Time to progressionPatients will be monitored for 5 years post-operativelytime from the date of the surgery until local, regional, or metastatic disease is detected
Disease Free SurvivalPatients will be monitored for 5 years post-operativelyTime from the date of the surgery until a patient experiences a recurrence, a new primary cancer or death
Progression-free survivalPatients will be monitored for 5 years post-operativelyTime from the date of the surgery until a patient shows sign of disease progression
Voice FunctionMeasure documented at time of surgical booking and at 1, 3, 6 and 12 months post-surgery, thereafter yearly for 5 years. (9 visits total)Measured by Voice Handicap Index -10

Countries

Canada

Contacts

Primary ContactPrisman Eitan, MD, FRCSC
eitan.prisman@gmail.com604-875-4126
Backup ContactOleksandr Butskiy, MD
butskiy.alex@gmail.com604-375-7529

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026